Project Grant R43NS105175

Novelmed Therapeutics, Inc. was awarded a $900,000 Project Grant from the National Institutes of Health's National Institute on Aging to develop a selective inhibitor of the alternative pathway of complement as a treatment for Neuromyelitis Optica Spectrum Disorder. Under the grant, Novelmed will conduct preclinical studies to evaluate its lead drug candidate NM5072, including in vitro and ex vivo assays to confirm the drug's mechanism of action and selective inhibition of the alternative...

The Regents of the University of California, San Francisco will conduct a randomized controlled trial of N-acetyl cysteine as a neuroprotective agent in progressive multiple sclerosis under a $2.2 million project grant from the Defense Health Agency. The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve health care for service members and the public. Specifically, the university will investigate medical...

The federal Project Grant award R61NS136656, "TARGETING THE ABCA1 CHOLESTEROL TRANSPORTER TO CORRECT PATHOPHYSIOLOGICAL MYELIN FORMATION IN HEREDITARY NEUROPATHIES", is funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The $352,073 award will support research by the University of Nevada, Reno to advance the development of a novel therapeutic drug...

This $647,782 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program supports research to evaluate the therapeutic potential of hypoxia mimetics in treating inflammatory demyelinating diseases like multiple sclerosis (MS). The key objectives are to: 1) Define an optimal treatment protocol using hypoxia mimetic drugs to accelerate...

The U.S. National Institute on Aging (NIA) awarded a $473,216 Project Grant (CFDA 93.866) to MCM6 Therapeutics, Inc. to conduct a high-content drug screening to identify small molecule therapeutics that can reduce aberrant lipid accumulation in APOE4-expressing oligodendrocytes, which is a key pathological feature of Alzheimer's disease. The project aims to adapt a screening assay to test a targeted library of ~2,500 lipid-modifying compounds, as well as perform a larger unbiased screen of...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $506,083 to Artificial Axon Labs Inc., an MIT spinout, to develop a biomimetic 3D-printed drug screening platform called "Artificial Axons." The platform aims to enable the discovery of remyelinating therapies for multiple sclerosis (MS) and other myelin diseases....

The federal Project Grant award R21AG089718, totaling $636,000.00, was provided by the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Pittsburgh. The grant aims to develop novel, orally bioavailable, and blood-brain barrier penetrant small molecule inhibitors of the NADPH oxidase 2 (NOX2) enzyme as a potential therapeutic strategy for treating Alzheimer's disease (AD) and related dementias. The key products and services to be delivered under this grant include:...

Novelmed Therapeutics, Inc. was awarded a $1,599,495 Project Grant from the National Heart, Lung and Blood Institute of the Department of Health and Human Services. The grant falls under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. Novelmed will use the funding to develop a novel disease-modifying treatment for paroxysmal nocturnal hemoglobinuria (PNH). The company's lead drug candidate selectively inhibits the alternative pathway of...

The National Institutes of Health National Institute on Aging awarded Arviat Pharmaceuticals, Inc. a $1,350,180 Project Grant under the Aging Research program (CFDA 93.866) on September 30, 2021 to develop novel small-molecule inhibitors of the 12/15-lipoxygenase enzyme family. The goal is to reduce neuroinflammation and slow disease progression in Alzheimer's disease by inhibiting 12/15-LO activity. Under the award, Arviat will screen compounds from existing patent portfolios and develop...

This $1,325,500 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop novel PAC1 receptor antagonists for the treatment of medication overuse headache (MOH). The primary objectives are to: Use computational modeling and virtual screening techniques to identify new small molecule PAC1 antagonists, as well as optimize the potency of an existing antagonist (PA8) through...